Article Type
Original Study
Abstract
Background: Because the aetiology of inflammatory bowel disease (IBD) is unclear, no causative therapy is available. However, pathophysiolo-gy of the disease offers a lot of possibilities to disrupt the inflammatory cascade that maintains the inflammatory process. Hyperleptinemia has been reported in acute inflammation especially during the early stage of intestinal inflammation. This study was done to investigate the potential therapeutic effect of B3 adrenoreceptor agonist BRI 37344 (BRI) and compare it with the traditional used pred-nisolone in an experimental model of inflammatory bowel disease. Methods : The present study was done on 40 rats. They were divided into 2 main groups: Group I: 10 rats, as control group, received distilled water. Group II: 30 rats, subdivided into 3 equal subgroups as follow: Subgroup lla: indomethacin only treated group, received 7.5mg/kg indomethacin for 2 doses separated by 24 hours, subcutaneously. Subgroup lib: indomethacin treated rats, received 0.5 mg/kg p red n is o I one intra-gastrically, with the 1st dose of indomethacin and for 4 consecutive days. Subgroup lie: indomethacin treated rats, received 1 mg/kg BRI intragastri-cally at the same time with the 1st dose of indomethacin
Recommended Citation
Abdel Malek, Hala; Hassanin, Amal; and Mohamed, Shihab
(2008)
"A STUDY OF THE POTENTIAL PROTECTIVE THERAPEUTIC EFFECT OF THE ANTI OBESITY DRUG BRI 37344 IN AN EXPERIMENTAL MODEL OF INFLAMMATORY BOWEL DISEASE,"
Mansoura Medical Journal: Vol. 37
:
Iss.
1
, Article 1.
Available at:
https://doi.org/10.21608/mjmu.2008.128907
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
